A Phase 4 interventional study of Pitavastatin (NK-104) and Darunavir/Ritonavir (Prezista) in Healthy, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-13.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 4, single center, open label, fixed-sequence, multiple dose, 2-way drug-drug interaction study.
This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.
Each subject will qualify for entry into the study not more than 30 days before admission into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline assessments. There will be 1 treatment period, with each subject receiving a once daily dose of pitavastatin 4 mg on Days 1 through 5 and Days 12 through 16 and a once daily dose of darunavir/ritonavir 800 mg/100 mg on Days 6 through 16. On Days 1 through 4, 6 through 10, and 12 through 15, study drug will be administered 30 minutes before a standard breakfast. On Days 5, 11, and 16, subjects will fast at least 8 hours before receiving study drug and remain fasted for 4 hours after dosing.
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pitavastatin 4 mg
Drug: Pitavastatin (NK-104) · Drug: Darunavir/Ritonavir (Prezista)
Pitavastatin (NK-104) 4mg once daily (QD)
Drug page: Darunavir/Ritonavir
Darunavir/Ritonavir (Prezista) 800 mg/100 mg
NK-104 AUC
Time frame: 16 Days
Number of Participants With at Least One Adverse Event.
Time frame: 16 Days
1st Subject Enrolled 20 April 2011 Last Subject Completed 10 June 2011
| Milestone | All Subjects |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
| Milestone | All Subjects |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
| Milestone | All Subjects |
|---|---|
| Started | 28 |
| Completed | 27 |
| Not completed | 1 |
| ng * h/mL | NK-104 |
|---|---|
| NK-104 AUC | 192.00 ± 80.8 |
| Participants | All Subjects |
|---|---|
| Number of Participants With at Least One Adverse Event. | 2 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | — | 0/28 (0%) | 13/28 (46.4%) |
| Event | All Subjects |
|---|---|
| HeadacheNervous system disorders | 3/28 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/28 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/28 |
| FatigueGeneral disorders | 2/28 |
| DiarrheaGastrointestinal disorders | 1/28 |
| ParesthesiaNervous system disorders | 1/28 |
| Abdominal painGastrointestinal disorders | 1/28 |
| NauseaGastrointestinal disorders | 1/28 |
| Swollen tongueGastrointestinal disorders | 1/28 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/28 |
| Age, Categorical(Participants) | All Subjects |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 28 |
| >=65 years | 0 |
| Age Continuous(years) | All Subjects |
|---|---|
| Mean | 30.5 ± 6.61 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 7 |
| Male | 21 |
| Region of Enrollment(participants) | All Subjects |
|---|---|
| United States | 28 |
The record gives a start of Apr 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pitavastatin · Darunavir/Ritonavir
Kowa Research Institute, Inc. →